These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9305372)

  • 1. Complications of intravenous immune globulin treatment in neurologic disease.
    Achiron A
    Neurology; 1997 Sep; 49(3):899-900. PubMed ID: 9305372
    [No Abstract]   [Full Text] [Related]  

  • 2. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis.
    Achiron A; Pras E; Gilad R; Ziv I; Mandel M; Gordon CR; Noy S; Sarova-Pinhas I; Melamed E
    Arch Neurol; 1992 Dec; 49(12):1233-6. PubMed ID: 1449400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined immunoglobulin and azathioprine in multiple sclerosis.
    Kalanie H; Tabatabai SS
    Eur Neurol; 1998; 39(3):178-81. PubMed ID: 9605396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome.
    Diener HC; Haupt WF; Kloss TM; Rosenow F; Philipp T; Koeppen S; Vietorisz A;
    Eur Neurol; 2001; 46(2):107-9. PubMed ID: 11528165
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
    Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
    Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012.
    Robert P; Hotchko M
    Transfusion; 2015 Jul; 55 Suppl 2():S6-12. PubMed ID: 26174899
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial.
    Poehlau D; Federlein J; Postert T; Sailer M; Bethke F; Kappos L; Haas J; Przuntek H
    Mult Scler; 1997 Apr; 3(2):149-52. PubMed ID: 9291171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results.
    Sørensen PS; Wanscher B; Schreiber K; Blinkenberg M; Jensen CV; Ravnborg M
    Mult Scler; 1997 Apr; 3(2):145-8. PubMed ID: 9291170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.
    Bayry J; Hartung HP; Kaveri SV
    Trends Pharmacol Sci; 2015 Jul; 36(7):419-21. PubMed ID: 26003802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
    Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
    Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study.
    Francis GS; Freedman MS; Antel JP
    Mult Scler; 1997 Dec; 3(6):370-6. PubMed ID: 9493636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin.
    Sorensen R
    J Manag Care Pharm; 2007 Apr; 13(3):278-83. PubMed ID: 17407395
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravenous immunoglobulins in multiple sclerosis.
    Lisak RP
    Neurology; 1998 Dec; 51(6 Suppl 5):S25-9. PubMed ID: 9851727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immune globulin for multiple sclerosis.
    Tecnologica MAP Suppl; 1998 Aug; ():3-5. PubMed ID: 10342975
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravenous immunoglobulin treatment in multiple sclerosis.
    Gadoth N; Melamed E; Miller A; Steiner I; Abramsky O
    Neurology; 1999 Jan; 52(1):214-5. PubMed ID: 9921886
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous immunoglobulin treatment in multiple sclerosis.
    Francis G
    Neurology; 1999 Jan; 52(1):214. PubMed ID: 9921885
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous gamma globulin in progressive MS.
    Cook SD; Troiano R; Rohowsky-Kochan C; Jotkowitz A; Bielory L; Mehta PD; Oleske J; Bansil S; Dowling PC
    Acta Neurol Scand; 1992 Aug; 86(2):171-5. PubMed ID: 1414228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.
    Sorensen PS; Wanscher B; Jensen CV; Schreiber K; Blinkenberg M; Ravnborg M; Kirsmeier H; Larsen VA; Lee ML
    Neurology; 1998 May; 50(5):1273-81. PubMed ID: 9595974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of intravenous immunoglobulin therapy.
    Ryan ME; Webster ML; Statler JD
    Clin Pediatr (Phila); 1996 Jan; 35(1):23-31. PubMed ID: 8825847
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous immunoglobulin for multiple sclerosis.
    Poser CM
    Lancet; 1997 Apr; 349(9059):1177-8. PubMed ID: 9113039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.